MorphoSys (ETR:MOR) has been given a €97.00 ($115.48) price target by equities researchers at JPMorgan Chase & Co. in a research report issued on Friday. The firm presently has a “buy” rating on the stock. JPMorgan Chase & Co.’s target price suggests a potential upside of 23.41% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. Independent Research set a €77.00 ($91.67) target price on shares of MorphoSys and gave the company a “buy” rating in a research note on Thursday, September 7th. Deutsche Bank set a €90.00 ($107.14) target price on shares of MorphoSys and gave the company a “buy” rating in a research note on Thursday, September 7th. Goldman Sachs Group set a €55.00 ($65.48) target price on shares of MorphoSys and gave the company a “neutral” rating in a research note on Tuesday, September 19th. Oddo Bhf set a €76.00 ($90.48) target price on shares of MorphoSys and gave the company a “buy” rating in a research note on Thursday, September 7th. Finally, Berenberg Bank set a €85.00 ($101.19) target price on shares of MorphoSys and gave the company a “buy” rating in a research note on Tuesday, November 7th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of €83.75 ($99.70).

Shares of MorphoSys (MOR) opened at €78.60 ($93.57) on Friday. MorphoSys has a 12 month low of €46.50 ($55.36) and a 12 month high of €83.83 ($99.80). The company has a market cap of $2,200.00 and a P/E ratio of -26.64.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/12/29/morphosys-mor-pt-set-at-97-00-by-jpmorgan-chase-co.html.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.